In following in vitro experiments, heterogeneously originated CAFs from breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinomas, were tested to be sensitive to cell death by hFAP-CAR T cells in vitro, broadening our FAP-CAR T cells use. The gene discussed is FAP; the disease is colorectal cancer.